- Home
- AMST vs BIVI Comparison
AMST vs BIVI Comparison
Compare AMST & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- BIVI
- Stock Information
- Founded
- AMST 2017
- BIVI 2013
- Country
- AMST United States
- BIVI United States
- Employees
- AMST N/A
- BIVI N/A
- Industry
- AMST Computer Software: Prepackaged Software
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- AMST Technology
- BIVI Health Care
- Exchange
- AMST Nasdaq
- BIVI Nasdaq
- Market Cap
- AMST 13.3M
- BIVI 11.9M
- IPO Year
- AMST 2020
- BIVI N/A
- Fundamental
- Price
- AMST $2.74
- BIVI $1.74
- Analyst Decision
- AMST
- BIVI
- Analyst Count
- AMST 0
- BIVI 0
- Target Price
- AMST N/A
- BIVI N/A
- AVG Volume (30 Days)
- AMST 14.0K
- BIVI 510.1K
- Earning Date
- AMST 09-29-2025
- BIVI 08-15-2025
- Dividend Yield
- AMST N/A
- BIVI N/A
- EPS Growth
- AMST N/A
- BIVI N/A
- EPS
- AMST N/A
- BIVI N/A
- Revenue
- AMST $82,544.00
- BIVI N/A
- Revenue This Year
- AMST N/A
- BIVI N/A
- Revenue Next Year
- AMST N/A
- BIVI N/A
- P/E Ratio
- AMST N/A
- BIVI N/A
- Revenue Growth
- AMST N/A
- BIVI N/A
- 52 Week Low
- AMST $2.00
- BIVI $1.42
- 52 Week High
- AMST $6.27
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- AMST 47.08
- BIVI 29.37
- Support Level
- AMST $2.63
- BIVI $1.54
- Resistance Level
- AMST $2.83
- BIVI $1.68
- Average True Range (ATR)
- AMST 0.13
- BIVI 0.14
- MACD
- AMST 0.01
- BIVI 0.25
- Stochastic Oscillator
- AMST 53.85
- BIVI 84.21
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.